MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

Novel Immunotherapeutic Approaches in Early and Late Melanoma

Novel Immunotherapeutic Approaches in Early and Late Melanoma

Jeffrey Weber, MD, PhD

New Therapeutic Developments in Gynecologic Malignancies

New Therapeutic Developments in Gynecologic Malignancies

Amanda Nickles Fader, MD

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

Bruna Pellini, MD

Small Cell Lung Cancer

Small Cell Lung Cancer

Jason Porter, MD

Bi-Specific Inhibitor & ADC in Lung Cancer

Bi-Specific Inhibitor & ADC in Lung Cancer

Chul Kim, MD, MPH

Immunotherapy in NSCLC: First Line for Advanced Disease

Immunotherapy in NSCLC: First Line for Advanced Disease

Balazs Halmos, MD, MS

Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors

Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors

Edgardo S. Santos, MD, FACP

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastasis (Part 2)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastasis (Part 2)

Mike Cusnir,MD

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastasis (Part 1)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastasis (Part 1)

Caio Max Rocha-Lima, MD, MS

Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies

Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies

Mark Pegram, MD & Joyce O’Shaughnessy, MD

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Luis E. Raez, MD, FACP

Kidney & Bladder Cancer: Targeted, Immuno & Other Strategies

Kidney & Bladder Cancer: Targeted, Immuno & Other Strategies

Pedro Barata, MD, MSc

Prostate Cancer: Diagnostic and Therapeutic Updates

Prostate Cancer: Diagnostic and Therapeutic Updates

Karine Tawagi, MD

Immunotherapy in Breast Cancer: Now & The Future

Immunotherapy in Breast Cancer: Now & The Future

Avan Armaghani, MD

HER-2 Disease: Amplification/Overexpression/Mutation in Breast Cancer

HER-2 Disease: Amplification/Overexpression/Mutation in Breast Cancer

Virginia Borges, MD

Triple Negative Breast Cancer: Optimal Strategies

Triple Negative Breast Cancer: Optimal Strategies

Mark Pegram, MD

Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates

Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates

Joyce O’Shaughnessy, MD

How Precision Medicine is Changing Gastric and Esophageal Cancer Management

How Precision Medicine is Changing Gastric and Esophageal Cancer Management

Mike Cusnir, MD

Colorectal Cancer: Incorporating Molecular Testing and Checkpoint Inhibitors to the Standard of Care

Colorectal Cancer: Incorporating Molecular Testing and Checkpoint Inhibitors to the Standard of Care

Cathy Eng, MD

Management of Malignant Hypercalcemia, Bone Metastases & Standard Precautions to Decrease Adverse Events

Management of Malignant Hypercalcemia, Bone Metastases & Standard Precautions to Decrease Adverse Events

Meri Muminovic, MD

How to Handle Myelotoxicity from Chemotherapy in 2024: From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection to the Three Cell Lines

How to Handle Myelotoxicity from Chemotherapy in 2024: From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection to the Three Cell Lines

Martin Dietrich, MD, PhD

What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others)

What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others)

Mayra Lima, ARNP

Management of Patients After CAR-T Therapy: Adverse Reactions and Follow Up

Management of Patients After CAR-T Therapy: Adverse Reactions and Follow Up

Brigett Brandjes, PA-C, MMSc

Targeted Therapy and Immunotherapy for Soft Tissue Tissue Sarcomas

Targeted Therapy and Immunotherapy for Soft Tissue Tissue Sarcomas

Jonathan Trent, MD

Challenges in Targeting Head and Neck Squamous Cell Carcinoma

Challenges in Targeting Head and Neck Squamous Cell Carcinoma

Noman Ashraf, MD

Update on T-Cell Lymphomas

Update on T-Cell Lymphomas

Juan Carlos Ramos, MD

Modern Challenges and New Options for B-cell NHL

Modern Challenges and New Options for B-cell NHL

Eduardo Sotomayor, MD

Most Relevant News in Multiple Myeloma in 2023

Most Relevant News in Multiple Myeloma in 2023

Sergio Giralt, MD, FACP, FASTCT

New Developments in CLL

New Developments in CLL

Javier Pinilla-Ibarz, MD, PhD

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

Jason Porter, MD